SCHEDULE: NEA Funds Drastically Cut Adaptimmune Stake

New Enterprise Associates funds significantly reduced their beneficial ownership in Adaptimmune Therapeutics Plc through recent open market sales.

Summary

• New Enterprise Associates (NEA) funds, including NEA 14 and NEA 16, filed an Amendment No. 3 to their Schedule 13D for Adaptimmune Therapeutics Plc.
• The filing reports significant open market sales of Adaptimmune's Ordinary Shares, represented by American Depositary Shares (ADSs).
• On August 15, 2025, NEA 14 sold 3,424,255 ADSs (20,545,530 Ordinary Shares) and NEA 16 sold 804,701 ADSs (4,828,206 Ordinary Shares) at a weighted average price of $0.0662 per ADS.
• On August 18, 2025, NEA 14 sold an additional 10,405,523 ADSs (62,433,138 Ordinary Shares) and NEA 16 sold 2,445,299 ADSs (14,671,794 Ordinary Shares) at a weighted average price of $0.0722 per ADS.
• Following these transactions, the NEA Funds collectively hold a total of 4 Ordinary Shares, representing 0% of the outstanding shares.
• The percentage of ownership is calculated based on 1,590,309,546 Ordinary Shares outstanding as of August 11, 2025.

Sentiment

Score: 2

Explanation: The filing indicates a complete divestment by a major institutional investor, New Enterprise Associates, which is a strong negative signal for the company's stock. While the filing itself is a routine disclosure, the underlying action of selling off the entire stake suggests a lack of confidence or a strategic exit by a significant holder.

Negatives

• Significant reduction in beneficial ownership by New Enterprise Associates funds, indicating a divestment strategy.
• The sale of a large number of shares (over 16 million ADSs, representing over 97 million Ordinary Shares) could exert downward pressure on the stock price.
• The reporting persons state they "may dispose of additional shares," suggesting potential for further sales.

Risks

• Potential for continued selling pressure on Adaptimmune Therapeutics Plc's stock if the reporting persons dispose of additional shares.
• Loss of a significant institutional investor's stake could be perceived negatively by the market, potentially impacting investor confidence.

Future Outlook

Depending on market conditions and other factors, the Funds and other Reporting Persons may dispose of additional shares of the Issuer.

Industry Context

This filing reflects a significant divestment by a venture capital firm from a biotechnology company. Such divestments can occur for various reasons, including portfolio rebalancing, reaching investment horizons, or a change in outlook on the company's prospects. In the biotech industry, early-stage investors often exit positions as companies mature or reach certain milestones, but a complete divestment to 0% is notable.

Stakeholder Impact

• Shareholders: Potential negative impact on share price due to selling pressure and perceived loss of institutional investor confidence.
• Company Management: May face questions regarding the reasons for the significant divestment by a major investor.

Next Steps

• The reporting persons may dispose of additional shares of the Issuer depending on market conditions and other factors.

Key Dates

Recommendation

The complete divestment by a major institutional investor like New Enterprise Associates, reducing their beneficial ownership to 0%, is a strong negative indicator. Such a move suggests a lack of long-term confidence or a strategic exit, which could lead to further downward pressure on the stock price and erode investor sentiment. While the filing itself is a disclosure, the underlying action of selling off the entire stake warrants a cautious or negative outlook for the stock.

Keywords

Adaptimmune Therapeutics Plc, ADAP, Schedule 13D, SEC filing, beneficial ownership, share sale, institutional investor, New Enterprise Associates, NEA, ordinary shares, American Depositary Shares, ADS